Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

zolbetuximab 2Oxaliplatin 2Afatinib 2trastuzumab deruxtecan 1tepotinib 1repotrectinib 1pralsetinib 1brigatinib 1Standard of Care 1Pemetrexed 1Leucovorin 1Fluorouracil 1Crizotinib 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Adenocarcinoma × Afatinib × Clear all
NCT01121393 2018-12-14

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Boehringer Ingelheim

Phase 3 Completed
364 enrolled 28 charts 1 FDA
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Boehringer Ingelheim

Phase 3 Completed
345 enrolled 23 charts 1 FDA
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡